TCGA-77-A5GB-01B-11R-A27Q-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 90
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- TNFA_SIGNALING_VIA_NFKB+0.310
- ALLOGRAFT_REJECTION+0.300
- MYC_TARGETS_V2+0.300
- ANGIOGENESIS+0.290
- PANCREAS_BETA_CELLS+0.280
- HYPOXIA+0.250
- MYC_TARGETS_V1+0.240
Top 10 suppressed
- ADIPOGENESIS-0.360
- PROTEIN_SECRETION-0.340
- BILE_ACID_METABOLISM-0.280
- FATTY_ACID_METABOLISM-0.220
- OXIDATIVE_PHOSPHORYLATION-0.220
- TGF_BETA_SIGNALING-0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.170
- ESTROGEN_RESPONSE_EARLY-0.150
- HEME_METABOLISM-0.140
- PEROXISOME-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F5EB77B4-61AD-40EC-B5B0-44D2D5AD66D7 | — | — | 0.824 |
| 2 | TCGA-22-4604-01A-01R-1201-07 | — | cohortSQ2 | 0.769 |
| 3 | TCGA-LL-A5YP-01A-21R-A28M-07 | — | E | 0.769 |
| 4 | 333376 | EPN | Supratentorial EPN | 0.762 |
| 5 | BS_WJ9H4NZZ | high-grade glioma | — | 0.762 |
| 6 | SJEPD001514_D1.RNA-Seq | EPN | Supratentorial EPN | 0.759 |
| 7 | TCGA-85-8276-01A-11R-2296-07 | — | cohortSQ1 | 0.758 |
| 8 | TCGA-GC-A3YS-01A-11R-A23N-07 | — | — | 0.748 |
| 9 | SRR5903558 | — | cohortMD2 | 0.745 |
| 10 | TCGA-68-8251-01A-11R-2296-07 | — | cohortSQ1 | 0.745 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |